Immunology

Public health

The high economic cost of Zika in Brazil

Families of children diagnosed with Congenital Zika Syndrome—which includes microcephaly—face high medical expenses, partly covered by the government

By

photolab

Narrow passage

Image shows how Leukocytes squeeze through tiny pores

By

Ecology

Vaccinating primates against yellow fever

Early trials suggest human vaccines are effective in wild primate species susceptible to the yellow fever virus

By

COVID-19

The quest for a Brazilian vaccine

Researchers are testing a range of technologies, but few initiatives will receive the funding needed for costly phase 3 clinical trials

By

Covid-19

Vaccines generate more consistent immune response

The immune response to the novel coronavirus provided by vaccines is more consistent than that triggered by natural infection with SARS-CoV-2

By

COVID-19

Two vaccines safe for children

The CoronaVac vaccine, produced in Brazil by the Butantan Institute, is safe for children and adolescents, with no major side effects

By

HEALTH

Pioneering immunization

Malaria vaccine recommended for children in Africa by the WHO is the first to protect humans from a parasite

By

Covid-19

Confidence in vaccines

Vaccination rate in Brazil greater than in developed countries

By

COVID-19

Vaccination in decline

The COVID-19 vaccination pace has been decreasing worldwide

By

Covid-19

Fewer vaccines for those who want them

In low- and middle-income countries the proportion of people who want to get vaccinated is considerably higher than in richer countries

By

COVID-19

Universal vaccine

Researchers are trying to develop a broad-spectrum vaccine capable of protecting people against all types of coronaviruses and their variants

By

COVID-19

Mixed protection

Preliminary studies suggest that combining two different vaccines could be useful in the fight against the pandemic

By

COVID-19

All eyes on ButanVac

New vaccine candidate uses a more stable version of the spike protein

By

COVID-19

Two vaccines prevent infection by Sars-CoV-2

Pfizer-BioNTech and Moderna vaccines are 80% effective at preventing SARS-Cov-2 infections after the first dose and 90% after the second

By

COVID-19

Superior immunity

Studies of blood and tissue samples taken before the COVID-19 pandemic may help explain why the disease is more common and more severe in adults than in children

By

photolab

Lethal networks

Faced with an invasion of viruses or bacteria, human immune system cells sometimes overreact in a process known as NETosis, which has been shown to be more severe when the invader is SARS-CoV-2

By

COVID-19

New vaccines on the way

Butantan Institute and federal government plan to start human trials of two vaccine candidates in the coming months

By and

INTERVIEW

Eurico Arruda: Admirer of viruses

Coronavirus specialist and USP physician speaks about the new variants of SARS-CoV-2 and the risk they represent in the efficacy of some vaccines

By

Covid-19

The expected effect of vaccines

Administering vaccines on a large scaled will tell us whether, in addition to protecting against the disease, they are also able to prevent infection by SARS-CoV-2

By

Covid-19

Obstacle course

Research centers working on vaccines for the novel coronavirus in Brazil face major hurdles

By

Covid-19

Antibodies reduce deaths

A clinical trial led by researchers at the University of Oxford, UK, identified a second drug capable of reducing mortality among patients with severe COVID-19

By

Public health

Vaccinations have prevented 37 million deaths in 98 countries

Immunization against major diseases has had a significant impact on public health in low- and middle-income countries, helping to save 37 million lives between 2000 and 2019

By

INTERVIEW

Dimas Covas: The trajectory of Butantan

The hematologist from USP readies the São Paulo institute to fight the pandemic and has plans to transform it into one of the world’s top producers of vaccines and serums

By and

COVID-19

vaccine. Now what?

The introduction of vaccines in the battle against the COVID-19 pandemic raises new challenges

By

COVID-19

A more balanced game

Approved for emergency use, CoronaVac is the first vaccine to be offered in Brazil

By

COVID-19

Yes to the vaccine

On January 18, FAPESP started the #vacinasim (“yesvaccine”) social media campaign to reinforce public confidence in their safety and effectiveness

By

COVID-19

Immunity could be long-lasting

The immune system's ability to recognize the novel coronavirus and fight it seems to last for at least eight months

By

COVID-19

The era of genetic vaccines

The vaccines from BioNTech/Pfizer and Moderna result from historical investments in messenger RNA technology leading to the creation of new products

By

COVID-19

Distribution challenges

Governments need to work with pharmaceutical and logistics companies to overcome obstacles to start the SARS-CoV-2 immunization campaign

By

COVID-19

Approval strategy

Amid uncertainty, São Paulo announces state vaccination plan

By